Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Highlights of prescribing information: Zometa (zoledronic acid). U.S. Food & Drug Administration. 2019 Dec 12.
  2. Rosen HN. Bisphosphonate therapy for the treatment of osteoporosis. Up-To-Date. 2022 Jul 21.
  3. Moore N, Noblet C, Kreft-Jais C, et al. La banque de cas du système français de pharmacovigilance: quelques exemples d’exploitation [French pharmacovigilance database system: examples of utilisation]. Therapie. 1995 Nov–Dec;50(6):557–562. French. PMID: 8745956.
  4. Amigues C, Fresse A, Roux C, et al. Zoledronate-related osteonecrosis of the jaw in osteoporosis: Incidence, risk factors and comparison to oral bisphosphonates [OP0240]. Ann Rheum Dis. 2022;81 (suppl 1):158.

Related Articles

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    BlurryMe / shutterstock.com

    The Prevention & Management of Medication-Related Osteonecrosis of the Jaw

    Medication-related osteonecrosis of the jaw (MRONJ) is a con­dition that manifests as exposed, necrotic and non-healing jaw bone in patients who have been treated with bisphosphonates, denosumab, chemotherapeutic agents, anti-angiogenic drugs, tyrosine kinase inhibitors, thalidomide and steroids.1-4 These medications are admin­istered via intravenous, subcutaneous and oral routes to manage osteopenia; osteoporosis; hypercalcemia of malignancy; bone…